RNS Number : 8120U IQ-AI Limited 03 August 2022 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which
RNS Number : 9294R IQ-AI Limited 11 July 2022 IQ-AI Limited (“IQ-AI” or the “Company”) Imaging Biometrics Announces Channel Partnership IQ-AI Limited (OTCQB: IQAIF) (LSE: IQAI), is pleased to announce that its medical imaging analysis software, IB Clinic®, is now available via the newly launched Bayer Calantic platform. This latest distribution partnership
RNS Number : 2442N IQ-AI Limited 30 May 2022 30 May 2022 IQ-AI Limited (“IQ-AI” or the “Company”) Result of AGM IQ-AI Limited announces that at the annual general meeting of the Company held earlier today, all resolutions were duly passed. The Directors of the Company accept responsibility for the
RNS Number : 3069N IQ-AI Limited 31 May 2022 31 May 2022 IQ-AI Limited (“IQ-AI” or the “Company”) Imaging Biometrics Submits FDA 510(k) Application for IB Zero G Patented Artificial Intelligence Technology Eliminates the Need for Gadolinium-Based Contrast Agents in MRI Exams Milwaukee – 31 May 2022: Imaging Biometrics, LLC (IB), a
RNS Number : 4440K IQ-AI Limited 05 May 2022 5 May 2022 IQ-AI Ltd (“IQ-AI” or the “Company”) Notice of AGM IQ-AI Limited announces that notice of the annual general meeting of the Company, to be held at Third Floor, Forum 4, Grenville Street, St Helier, Jersey, JE2 4UF on 30
RNS Number : 7683J IQ-AI Limited 28 April 2022 28 April 2022 IQ-AI Ltd (“IQ-AI”, the “Company” and, together with its subsidiaries, the “Group”) Publication of Annual Report The Board of IQ-AI Ltd are pleased to present announce that the Company’s audited financial statements for the year ended 31 December 2021.
RNS Number : 2319E IQ-AI Limited 09 March 2022 FOR IMMEDIATE RELEASE IQ-AI LIMITED (“IQ-AI” or the “Company”) IQAI’s Sponsored Phase I Clinical Trial is Open Milwaukee – 9 March 2022: IQ-AI Limited (OTCQB: IQAIF) (LSE: IQAI) is pleased to announce that the sponsored Phase I clinical trial for oral gallium maltolate (GaM) is
RNS Number : 0358D IQ-AI Limited 28 February 2022 28 February 2022 IQ-AI Ltd (“IQ-AI” or the “Company”) Total Voting Rights In accordance with the Financial Conduct Authority’s Disclosure and Transparency Rules, IQ-AI announces that the Company has 182,621,390 ordinary shares of 1p each in issue, none of which are held in
RNS Number : 9343A IQ-AI Limited 08 February 2022 8 February 2022 IQ-AI Ltd (“IQ-AI” or the “Company”) Issue of shares to Mayo Clinic Further to the Company’s announcement dated 9 November 2020, IQ-AI announces the allotment of 113,781 ordinary shares of 1p each in IQ-AI (the “New Ordinary Shares”) to Mayo
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.